The IL-23 inhibitor from AbbVie indicated for the treatment of adults with
active psoriatic arthritis (PsA) and for moderate to severe plaque psoriasis (Ps)
in adults who are candidates for systemic therapy or phototherapy.1

The IL-23 inhibitor from AbbVie indicated for the treatment of adults with: active psoriatic arthritis (PsA);
moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy; moderately
to severely active Crohn's disease (CD); or moderately to severely active ulcerative colitis (UC)

Nothing is Everything.

FOR ADULTS WITH ACTIVE PSORIATIC ARTHRITIS (PsA)1

Nothing less than the opportunity
to reach for their treatment goals

For your patients,
that’s everything.

#1 Prescribed First-line Biologic by Rheumatologists for PsA *”First-line” is defined as the first biologic prescription among patients who have not been prescribed biologics in the last 3 years. †Source: IQVIA (NPA, NSP) and Symphony Health data through March 2025.

AFTER NSAIDs OR csDMARDs,

MAKE SKYRIZI YOUR FIRST CHOICE
FOR BIO-NAÏVE PATIENTS WITH PsA

Learn why rheumatologists may start with SKYRIZI

SUSTAINED
RELIEF IN JOINTS AND SKIN

  • ACR20 primary endpoint met at Week 241
  • ACR20/50/70 and PASI 90 response rates at Week 24 and observed up to ~5 years3
SEE SUSTAINED RELIEF IN JOINTS
SEE SUSTAINED RELIEF IN SKIN

SAFETY
AND TOLERABILITY

  • Up to 6 years of PsA safety data and ~9 years in Ps4,‡
  • Discontinuation rates evaluated at Week 24 and 6 years in PsA.5-7
  • Safety profile of PsA at Week 24 was generally consistent with Ps at Week 161
MORE ABOUT SAFETY AND TOLERABILITY

SIMPLE
TO START

  • Initially evaluate for TB, instruct patients to report signs and symptoms of infection, and provide proper administration training1
  • Quarterly dosing after 2 initiation doses at Weeks 0 and 4 (150 mg/dose) with 2 administration options1
SEE DOSING AND ADMINISTRATION

‡Includes 5 PsA Phase 2-3 studies (including KEEPsAKE-1 and KEEPsAKE-2). Includes 23 Phase 1-4 studies in Ps encompassing 5 trials (including UltIMMa-1, UltIMMa-2, IMMhance, and IMMVent), and 18 additional trials including LIMMitless.4

Exceptional Immunology Experience

In rheumatology

#1 prescribed first-line biologic by rheumatologists for PsA

*”First-line” is defined as the first biologic prescription among patients who have not been prescribed biologics in the last 3 years.

†Source: IQVIA (NPA, NSP) and Symphony Health data through March 2025.

IN GASTROENTEROLOGY

#1 prescribed biologic in Crohn's & UC

§Source: Symphony Health an ICON plc COMPANY, IDV®; January 2025 to March 2025.

In dermatology

#1 prescribed branded systemic by dermatologists for patients with psoriatic disease

Based on combined prescription data across Ps and PsA, excluding generics and OTC

||Source of data: Integrated Symphony Health as of 3/2024.

SKYRIZI IS COVERED AS A 

FIRST-LINE ADVANCED THERAPY

WITH NO REQUIREMENT OF A PRIOR BIOLOGIC, WITH

Approximately 99% preferred combined commercial and medical Part D coverage

National Commercial and Medicare Part D Formulary coverage under the pharmacy benefit as of August 2025.11

First-line advanced therapies consist of PDE4is, TNFis, and other biologics.

#SKYRIZI is on a preferred tier or otherwise has preferred status on the plan's formulary.

**Coverage requirements and benefit designs vary by payer and may change over time. 

Please consult with payers directly for the most current reimbursement policies.

WHAT MAY AFFORDABILITY MEAN FOR YOUR PATIENTS?

$0

Eligible, commercially insured patients may pay as little as $0 per dose, four times a year††

††Eligibility: Available to patients with commercial insurance coverage for SKYRIZI® (risankizumab-rzaa) who meet eligibility criteria. This co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. For full Terms and Conditions, visit SKYRIZISavingsCard.com or call 1.866.SKYRIZI for additional information. To learn about AbbVie's privacy practices and your privacy choices, visit https://abbv.ie/corpprivacy

VIEW COVERAGE AND ACCESS

NO CHARGE FOR ELIGIBLE, COMMERCIALLY INSURED PATIENTS EXPERIENCING INITIAL INSURANCE DENIAL FOR UP TO 24 MONTHS‡‡

Download or email Skyrizi Complete Enrollment and Prescription Form

DOWNLOAD
EMAIL

‡‡Eligibility criteria: Available to patients aged 63 or younger with commercial insurance coverage. Patients must have a valid prescription for SKYRIZI® (risankizumab-rzaa) for an FDA approved indication and a denial of insurance coverage based on a prior authorization request on file along with a confirmation of appeal. Continued eligibility for the program requires the submission of an appeal of the coverage denial every 180 days. Program provides for SKYRIZI® (risankizumab-rzaa) at no charge to patients for up to two years or until they receive insurance coverage approval, whichever occurs earlier, and is not contingent on purchase requirements of any kind. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Offer subject to change or discontinuance without notice. This is not health insurance and program does not guarantee insurance coverage. No claims for payment may be submitted to any third party for product dispensed by program. Limitations may apply.

ACR20/50/70=≥20%/50%/70% improvement in tender joint count, swollen joint count, and at least 3 other core criteria; csDMARD=conventional synthetic disease-modifying antirheumatic drug; NPA=National Prescription Audit; NSAID=nonsteroidal anti-inflammatory drug; NSP=National Sales Perspectives; PASI 90=≥90% improvement in Psoriasis Area and Severity Index; PDE4i=phosphodiesterase-4 inhibitor; Ps=psoriasis; PsA=psoriatic arthritis; TNFi=tumor necrosis factor inhibitor